Detalhe da pesquisa
1.
The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.
Nat Immunol
; 25(6): 1020-1032, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38831106
2.
An NK-like CAR T cell transition in CAR T cell dysfunction.
Cell
; 184(25): 6081-6100.e26, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861191
3.
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas.
Blood
; 143(9): 822-832, 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048694
4.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194692
5.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
N Engl J Med
; 386(7): 629-639, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904798
6.
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.
Blood
; 142(20): 1724-1739, 2023 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37683180
7.
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437622
8.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Lancet
; 402(10402): 641-654, 2023 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295445
9.
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy.
Blood
; 139(7): 1026-1038, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34496014
10.
Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy.
Mol Ther
; 31(3): 686-700, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36641624
11.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33259589
12.
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Am J Hematol
; 98(5): 739-749, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36810799
13.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Lancet Oncol
; 23(8): 1055-1065, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35803286
14.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628
15.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 380(1): 45-56, 2019 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30501490
16.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 22(10): 1403-1415, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34516954
17.
CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before.
Br J Haematol
; 193(3): 449-465, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222167
18.
Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Cancer Immunol Immunother
; 70(3): 869-874, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32857184
19.
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.
Haematologica
; 106(6): 1705-1713, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32414850
20.
Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
Hematol Oncol
; 39 Suppl 1: 113-116, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34105818